AURA
NASDAQAura Biosciences Inc.
Price$6.98+0.17 (+2.50%)
01:30 PM07:45 PM
News · 26 weeks55-14%
2026-01-182026-07-12
Mix3690d
- SEC Filings14(39%)
- Insider11(31%)
- Other5(14%)
- Offering4(11%)
- Leadership2(6%)
Latest news
25 items- INSIDERDirector Bender Jeremy was granted 30,000 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bender Jeremy3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECAura Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of DirectorsBOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. "I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again," said Natalie Holles, Chief Executive Officer of Aura Biosciences. "Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development, commercialization and significant value creation in rare oncology. As Aura advances toward poten
- INSIDEROfficer Kilroy Conor was granted 14,858 shares, increasing direct ownership by 7% to 232,693 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECSEC Form DEF 14A filed by Aura Biosciences Inc.DEF 14A - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form PRE 14A filed by Aura Biosciences Inc.PRE 14A - Aura Biosciences, Inc. (0001501796) (Filer)
- INSIDEROfficer Gibney Anthony S sold $82,330 worth of shares (12,824 units at $6.42), decreasing direct ownership by 5% to 265,354 units (SEC Form 4) to cover withholding tax4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERDirector Srivastava Sapna was granted 15,000 shares, increasing direct ownership by 64% to 38,500 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERDirector Bitetti Teresa Marie was granted 15,000 shares, increasing direct ownership by 71% to 36,000 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERDirector Johnson David Michael was granted 15,000 shares, increasing direct ownership by 8% to 194,167 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERDirector Mattessich Antony C. was granted 15,000 shares, increasing direct ownership by 64% to 38,500 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- PRAura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal MelanomaEnrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027. "Completing enrollment in our Pha
- INSIDEROfficer Holles Natalie C. was granted 1,153,962 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- PRAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, "Inducement Awards") were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the "Grant Date"). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Awards consist of (i) non-qualified stock
- SECSEC Form S-8 filed by Aura Biosciences Inc.S-8 - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form SCHEDULE 13G filed by Aura Biosciences Inc.SCHEDULE 13G - Aura Biosciences, Inc. (0001501796) (Subject)
- PRAura Biosciences to Participate in Upcoming Investor ConferencesBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026. Fireside Chat at 12:00 p.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026. Fireside Chat at 1:30 p.m. ET The live webcasts of the fireside chats will be available on the "Investors & Media" page under the "Events &
- INSIDERLarge owner Matrix Capital Management Company, Lp sold $39,044,987 worth of shares (6,922,870 units at $5.64) (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECSEC Form 10-Q filed by Aura Biosciences Inc.10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aura Biosciences Inc.SCHEDULE 13D/A - Aura Biosciences, Inc. (0001501796) (Subject)
- SECAura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsPhase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. "We are entering a pivotal period for Aura as
- INSIDERSEC Form 3 filed by new insider Holles Natalie C.3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECAura Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Aura Biosciences, Inc. (0001501796) (Filer)
AURA FAQ
7 questionsWhat does Aura Biosciences Inc. do?
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Where does AURA stock trade?
Aura Biosciences Inc. (AURA) is listed on NASDAQ.What sector and industry is AURA in?
Aura Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Aura Biosciences Inc. go public?
Aura Biosciences Inc. (AURA) completed its IPO in 2021.What are analysts saying about AURA?
Aura Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform with a $1300.00 price target on 2025-11-26. Recent price targets range from $1300.00 to $4000.00.What companies are similar to AURA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AURA side-by-side with any of them on Quantisnow.How can I track AURA on Quantisnow?
Quantisnow aggregates Aura Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AURA to receive live email and push alerts on every new disclosure.